Efficacy and Safety of Intravenous Immunoglobulin for Immune-Mediated Skin Disease: Current View

ISSN： 1175-0561

Source： American Journal of Clinical Dermatology, Vol.5, Iss.3, 2004-01, pp. : 153-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravenous Immunoglobulin Therapy in Autoimmune Mucocutaneous Blistering Diseases: A Review of the Evidence for its Efficacy and Safety

By Gürcan Hakan M. Jeph Sunil Ahmed A. Razzaque

American Journal of Clinical Dermatology, Vol. 11, Iss. 5, 2010-10 ,pp. : 315-326

Adis International

Access to resources Recommend Favorite

Management of Immune-Mediated Uveitis

By Smith J.R. Rosenbaum J.T.

BioDrugs, Vol. 13, Iss. 1, 2000-01 ,pp. : 9-20

Adis International

Access to resources Recommend Favorite

Pathophysiology of Immune-Mediated (Type 1) Diabetes Mellitus: Potential for Immunotherapy

By Abel M. Krokowski M.

BioDrugs, Vol. 15, Iss. 5, 2001-05 ,pp. : 291-301

Adis International

Access to resources Recommend Favorite

Use of Intravenous Immunoglobulin in Multiple Sclerosis

By Achiron A.

BioDrugs, Vol. 9, Iss. 6, 1998-06 ,pp. : 465-475

Adis International

Access to resources Recommend Favorite

Mechanisms of Intravenous Immunoglobulin Action in the Treatment of Autoimmune Disorders

By Larroche C.

BioDrugs, Vol. 16, Iss. 1, 2002-01 ,pp. : 47-55

Adis International

Access to resources Recommend Favorite